Compare SSNC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSNC | SNN |
|---|---|---|
| Founded | 1986 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | 16988 |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 14.3B |
| IPO Year | 2007 | N/A |
| Metric | SSNC | SNN |
|---|---|---|
| Price | $69.30 | $31.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $96.13 | $36.25 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 04-23-2026 | 03-16-2026 |
| Dividend Yield | 1.55% | ★ 2.48% |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $1,675,295,000.00 | N/A |
| Revenue This Year | $9.20 | $8.58 |
| Revenue Next Year | $4.69 | $5.60 |
| P/E Ratio | $76.03 | ★ $64.97 |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $65.05 | $28.23 |
| 52 Week High | $91.07 | $38.79 |
| Indicator | SSNC | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 42.23 |
| Support Level | $65.48 | N/A |
| Resistance Level | $72.89 | $33.89 |
| Average True Range (ATR) | 1.71 | 0.57 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 47.07 | 23.11 |
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. Acquisitions are a large part of SS&C's history. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.